Unknown

Dataset Information

0

NGR-peptide-drug conjugates with dual targeting properties.


ABSTRACT: Peptides containing the asparagine-glycine-arginine (NGR) motif are recognized by CD13/aminopeptidase N (APN) receptor isoforms that are selectively overexpressed in tumor neovasculature. Spontaneous decomposition of NGR peptides can result in isoAsp derivatives, which are recognized by RGD-binding integrins that are essential for tumor metastasis. Peptides binding to CD13 and RGD-binding integrins provide tumor-homing, which can be exploited for dual targeted delivery of anticancer drugs. We synthesized small cyclic NGR peptide-daunomycin conjugates using NGR peptides of varying stability (c[KNGRE]-NH2, Ac-c[CNGRC]-NH2 and the thioether bond containing c[CH2-CO-NGRC]-NH2, c[CH2-CO-KNGRC]-NH2). The cytotoxic effect of the novel cyclic NGR peptide-Dau conjugates were examined in vitro on CD13 positive HT-1080 (human fibrosarcoma) and CD13 negative HT-29 (human colon adenocarcinoma) cell lines. Our results confirm the influence of structure on the antitumor activity and dual acting properties of the conjugates. Attachment of the drug through an enzyme-labile spacer to the C-terminus of cyclic NGR peptide resulted in higher antitumor activity on both CD13 positive and negative cells as compared to the branching versions.

SUBMITTER: Enyedi KN 

PROVIDER: S-EPMC5456102 | BioStudies | 2017-01-01

REPOSITORIES: biostudies

Similar Datasets

1000-01-01 | S-EPMC5942373 | BioStudies
2018-01-01 | S-EPMC6269559 | BioStudies
1000-01-01 | S-EPMC2838331 | BioStudies
2010-01-01 | S-EPMC3472425 | BioStudies
2020-01-01 | S-EPMC7486978 | BioStudies
2008-01-01 | S-EPMC2505196 | BioStudies
1000-01-01 | S-EPMC6271277 | BioStudies
2009-01-01 | S-EPMC2891414 | BioStudies
2018-01-01 | S-EPMC6088213 | BioStudies
2020-01-01 | S-EPMC7428931 | BioStudies